Case Study: Biotech Market Sizing: Reconciling a 3× Cell & Gene Therapy TAM

This biotech market sizing case study shows how PerspireIP builds a defensible total addressable market for a cell & gene therapy company when the published forecasts disagree with one another by threefold. Sizing an early biotech sub-sector is where market models most often break: vendor reports draw the boundary of the market differently, approval timelines are lumpy, and a founder can find a report to support almost any story. The worked example below is representative — assembled from public market data and the FDA’s own approval record — but the bottom-up method is exactly the one we run on a live engagement.

The Challenge

A venture-backed biotech held a delivery-vector and manufacturing platform that attaches to autologous cell and gene therapies — roughly 30 granted and pending patent families. It was raising a Series B, and the deck led with a total addressable market lifted from a single market report that put the cell & gene therapy market on a path past $140 billion. The trouble was that a second report, equally reputable, projected barely a third of that figure over the same horizon, and a narrower gene-therapy-only study came in lower still.

An investor’s diligence analyst had already flagged the discrepancy. When a headline TAM can be tripled or cut to a third by swapping which report you cite, the number stops persuading anyone. The company asked us for a biotech market sizing case study of its own segment — a bottom-up model it could defend line by line in the data room, with the divergence between the published figures explained rather than buried.

Our Approach to This Biotech Market Sizing Case Study

This biotech market sizing case study ran through three proven steps. Each answers a question the previous one leaves open, and together they turn three contradictory report headlines into one number a founder can defend:

1. Step 1 — Reconcile the published figures on one definition. Restate every third-party forecast against a single, explicit boundary for what counts as the market — cell therapy only, gene therapy only, or both, and with or without contract manufacturing — so the reports become comparable before any of them is trusted.
2. Step 2 — Build the market bottom-up from an observable unit. Derive the total from approved products × treated-patient population × net price per therapy, so every input is a number an investor can independently check against the public record.
3. Step 3 — Corroborate and layer TAM, SAM and SOM. Cross-check the bottom-up total against the reconciled band and the FDA approval trajectory, then carry the assumptions forward into a serviceable and obtainable market.

We refused to start from any single published headline. The observable anchors were public. Precedence Research put the global cell & gene therapy market at roughly $8.94 billion in 2025 on an 18.1% forecast CAGR to about $47.18 billion by 2035; Fortune Business Insights started higher, near $12.21 billion in 2025, and compounded at 31.1% to roughly $143.55 billion by 2034. A narrower gene-therapy-only read from Grand View Research — about $5.5 billion in 2023 — bracketed the low end. Three studies, one market, and a threefold spread by the end of the horizon.

The bottom-up driver was the approved product. The FDA’s Center for Biologics Evaluation and Research lists 59 approved cellular and gene therapy products as of August 2026 — a hard, regulator-published count, not a vendor projection. So we sized the market as approved and near-term products, multiplied by the eligible patient population each one treats, multiplied by the net price per course — a chain in which every link is a number an investor can check, rather than a market-share percentage asserted against a headline. Because approved cell and gene therapies carry some of the highest one-time list prices in medicine, a small treated population produces a large market, so the patient-count assumption is where the model has to be most honest.

Keeping the three layers separate mattered as much as the arithmetic. The TAM is the whole cell & gene therapy market the client’s platform could theoretically serve; the SAM is the slice reachable given its vector type, indication focus and patent rights; the SOM is the share realistically winnable over the funding horizon. A TAM quoted as if it were revenue is exactly the mistake the original deck made, and the one a diligence analyst spots first.

What the Research Found

Three findings shaped the reconciled range:

• The divergence was a definition problem, not a data problem. The published forecasts diverged mostly because each drew the boundary of the market differently — cell therapy plus gene therapy versus gene therapy alone, and finished product versus product-plus-contract-manufacturing. Precedence’s 2025 base of about $8.94 billion sat roughly 37% below Fortune Business Insights’ $12.21 billion for the same year, and the endpoint gap widened to nearly threefold because the two also assumed very different growth rates (18.1% versus 31.1%). Restating them on one definition collapsed most of the gap.
• The bottom-up total landed inside the reconciled band. Building from approved products × eligible patients × net price produced a TAM that sat between the conservative and aggressive third-party figures — corroboration from an independent method, which is what an analyst actually trusts.
• The approval trajectory supported the demand story. A cumulative 59 FDA-approved cell and gene therapy products, with oncology the single largest indication at roughly 39% of the market and viral vectors carrying about 72% of delivery, showed the client’s area compounding rather than cresting — a demand signal independent of any market report.

Where our bottom-up model and the reconciled third-party band overlapped, the client had a TAM it could defend; where they diverged, we documented exactly why, which is what a sharp investor looks for first.

The Outcome

The biotech market sizing case study replaced a single contestable headline with a bottom-up model whose every input traced to a cited source, plus a one-page reconciliation showing why the published reports disagreed. In the scenario, that turned the analyst’s objection into a strength — the founder could now walk the data room through the number instead of defending a citation.

The SAM layer did double duty: it became the go-to-market narrative (which indications and vector types the client’s platform could realistically serve), while the SOM layer set a credible revenue ramp for the model. One market model, consistent from the pitch narrative through to the financial projections, with no drift between the story and the spreadsheet.

What This Means for Similar Matters

The pattern generalises to any biotech market sizing case study in a fast-moving therapeutic field:

• Never lead with one report’s headline in a category where reports disagree — reconcile them on a single market definition first.
• Build bottom-up from an observable unit (here, approved products × eligible patients × net price); a derived total beats an asserted market share every time.
• Anchor to the regulator’s own record. An FDA approval count is a fact a skeptic cannot wave away, unlike a forecast CAGR.
• Log every assumption, especially the eligible-patient count — in a market of seven-figure one-time therapies, that single input moves the TAM more than any other.

A market sized this way does not just survive diligence — it shifts the burden to the skeptic to explain why a fully-sourced, independently-corroborated number is wrong.

Why Early Biotech Markets Resist Sizing

Cell and gene therapy sub-segments are among the hardest markets to size, and the reasons are structural rather than a failing of any one analyst. Approvals arrive in lumps — a handful of products in a year, each opening a distinct indication — so a straight-line growth curve misreads a market that actually steps. Definitions are contested: one house counts finished therapies, another folds in the contract manufacturing capacity that makes them, a third counts only gene therapies and excludes engineered cell therapies entirely. And pricing is unlike any other market, with single-course list prices reaching into seven figures, so a small change in the assumed patient population swings the total by billions.

That is precisely why a bottom-up model wins in a data room. When the unit of demand is an approved product treating a definable patient population at a knowable net price, the analyst can rebuild the total from first principles and check it against the reconciled reports. The method does not pretend the uncertainty away; it makes the uncertainty explicit and bounded, which is the most an honest market model can promise in a field moving this fast.

How the Market Number Fed the Financing

A sized market is only useful if it drives a decision, so we built the model to serve the raise directly. The reconciled TAM set the ceiling of the opportunity narrative; the SAM — the indications and vector types the client’s platform could realistically serve — became the addressable-market slide investors actually underwrite; and the SOM, tied to a credible ramp of platform deals over the funding horizon, anchored the revenue line in the financial model.

Because all three layers came from one traceable model, the pitch narrative and the spreadsheet could not drift apart — a common failure where the market slide claims one story and the projections quietly assume another. In the scenario, that internal consistency was what let the founder move the conversation from “which report do we believe?” to “here is how we capture our share,” which is the only market question a term sheet actually rewards.

Data Sources

The market and patent data referenced above comes from:

• FDA / CBER — Approved Cellular and Gene Therapy Products — The regulator's own list — 59 approved cell and gene therapy products as of August 2026, the bottom-up anchor
• Precedence Research — Cell and Gene Therapy Market — Market ~$8.94B (2025) → ~$47.18B (2035) at 18.1% CAGR; North America ~50.3% share; segment breakdowns
• Fortune Business Insights — Cell and Gene Therapy Market — Higher base of ~$12.21B (2025) compounding at 31.1% to ~$143.55B (2034) — the aggressive end of the reconciled band
• Grand View Research — Gene Therapy Market — Narrower gene-therapy-only read (~$5.5B in 2023, 18.9% CAGR) bracketing the low end of the definitional range

Discuss a Biotech Market Sizing Engagement

Turn a contestable headline into a number your investors and licensees will accept.

Related PerspireIP work: Market Sizing & Opportunity Analysis · Biotechnology & Pharma Patent Landscape · Semiconductor Market Sizing Case Study.

Frequently Asked Questions